X0306 4 2018-08-30 0 0001619087 SteadyMed Ltd. STDY 0001010208 STARK BRIAN JAY C/O STEADYMED THERAPEUTICS, INC. 2603 CAMINO RAMON, SUITE 350 SAN RAMON CA 94583 1 0 1 0 Ordinary Shares 2018-08-30 4 S 0 2937938 4.46 D 0 D Ordinary Shares 2018-08-30 4 S 0 1166428 4.46 D 0 I See Footnote Ordinary Shares 2018-08-30 4 S 0 15780 4.46 D 0 I See Footnote Ordinary Shares 2018-08-30 4 S 0 253309 4.46 D 0 I See Footnote Ordinary Shares 2018-08-30 4 S 0 323500 4.46 D 0 I By Debra Altshul Stark Stock Option (Rt to Buy) 5.60 2018-08-30 4 J 0 33350 0.00 D 2025-08-06 Ordinary Shares 33350 0 D Stock Option (Rt to Buy) 3.85 2018-08-30 4 J 0 3875 0.00 D 2026-10-05 Ordinary Shares 3875 0 D Stock Option (Rt to Buy) 3.65 2018-08-30 4 J 0 21029 0.00 D 2027-12-28 Ordinary Shares 21029 0 D Warrants to Purchase Ordinary Shares 3.5995 2018-08-30 4 J 0 939428 0.125 D 2021-08-03 Ordinary Shares 939428 0 D Warrants to Purchase Ordinary Shares 6.785 2018-08-30 4 J 0 209650 0.125 D 2022-04-24 Ordinary Shares 209650 0 D Warrants to Purchase Ordinary Shares 3.5995 2018-08-30 4 J 0 371375 0.125 D 2021-08-03 Ordinary Shares 371375 0 I See Footnote. Warrants to Purchase Ordinary Shares 6.785 2018-08-30 4 J 0 41875 0.125 D 2022-04-24 Ordinary Shares 41875 0 I See Footnote. Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). By Brown Bear Holdings LP. Stark Raving Mad LLC is the GP of the Partnership and the Reporting Person is the sole manager of the GP. By the Stark Family Trust. The Reporting Person is the trustee of the Stark Family Trust. By Brian Stark and Debra Altshul Stark. Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time. Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2016 was converted into the right to receive $2.71. Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2017 was converted into the right to receive $2.33. /s/ David W. Nassif, Attorney-In-Fact 2018-09-04